These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20964458)

  • 21. New anticoagulants - promising and failed developments.
    Harenberg J; Marx S; Krejczy M; Wehling M
    Br J Pharmacol; 2012 Jan; 165(2):363-72. PubMed ID: 21740405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
    Bátorová A
    Vnitr Lek; 2009 Mar; 55(3):295-301. PubMed ID: 19378862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.
    Hagemeyer CE; Tomic I; Jaminet P; Weirich U; Bassler N; Schwarz M; Runge MS; Bode C; Peter K
    Thromb Haemost; 2004 Jul; 92(1):47-53. PubMed ID: 15213844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
    Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U
    Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New anticoagulants and their potential impact on the treatment of thromboembolic disease.
    Ansell J
    Curr Hematol Rep; 2004 Sep; 3(5):357-62. PubMed ID: 15341703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
    Steffel J; Lüscher TF
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
    Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
    Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.
    Wong PC; Pinto DJ; Zhang D
    J Thromb Thrombolysis; 2011 May; 31(4):478-92. PubMed ID: 21318583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation by factor Xa inhibitors.
    Orfeo T; Butenas S; Brummel-Ziedins KE; Gissel M; Mann KG
    J Thromb Haemost; 2010 Aug; 8(8):1745-53. PubMed ID: 20492473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do Oral Factor Xa Inhibitors have a Role in Patients with Mechanical Heart Valves?
    Li S; Zhang Y
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):595-600. PubMed ID: 35869411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging anticoagulants.
    Kennedy B; Gargoum FS; Kennedy L; Khan F; Curran DR; O'Connor TM
    Curr Med Chem; 2012; 19(20):3388-416. PubMed ID: 22680641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux).
    Samama MM; Gerotziafas GT
    Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.